FDA fast tracks epcoritamab for follicular lymphoma
COPENHAGEN - The U.S. Food and Drug Administration (FDA) has granted Priority Review for epcoritamab, a potential new treatment for patients with relapsed or refractory follicular lymphoma, announced Genmab A/S (NASDAQ: NASDAQ:GMAB) and AbbVie (NYSE: NYSE:ABBV). This designation could significantly expedite the therapy\'s approval process, with a target action date set for June 28, 2024....